Logo wahanariau.com
  2. Io therapeutics

Io therapeutics

Index
Globenewswire

Io Therapeutics, Inc. announces publication of studies on the company’s RXR agonist compound IRX4204 for breast cancer prevention

Kamis, 12 Maret 2026 - 20:05:42 Wib
Globenewswire

Io Therapeutics, Inc., presents today at the San Antonio Breast Cancer Symposium preclinical studies demonstrating effectiveness of IRX4204, the company’s clinical stage retinoid X nuclear receptor (RXR) agonist compound, for synergistically promoting kil

Jumat, 12 Desember 2025 - 17:41:10 Wib
Globenewswire

Io Therapeutics Presents Today at the American Society for Hematology Annual Meeting, Preclinical Studies Demonstrating Combination Treatment with BCMA CAR-T Cells Plus the Company's RXR Agonist Compound IRX4204 has Synergistic Efficacy Against Human Mult

Senin, 08 Desember 2025 - 21:46:00 Wib
Globenewswire

Scientists Report Studies Showing a Novel Drug Repairs Myelin and Restores Nervous System Function in a Model of Multiple Sclerosis

Selasa, 24 Desember 2024 - 11:34:53 Wib
Globenewswire

Io Therapeutics, Inc., Announces Presentation of Data from Studies of its RAR Gamma Agonist Compound IRX5010 in Treatment of a Mouse Model of Triple Negative Breast Cancer, Demonstrating Combination Treatment Effects with an Anti-PDL-1 Monoclonal Antibody

Kamis, 12 Desember 2024 - 05:14:47 Wib
Globenewswire

Io Therapeutics, Inc., Presented Data From Studies of IRX4204, the Company’s Phase II Clinical Stage RXR Agonist for Treatment of Normal Aging-related Neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brai

Rabu, 18 September 2024 - 22:30:00 Wib
Globenewswire

Io Therapeutics, Inc., Presented Today Results from Studies of IRX4204, the Company’s Phase II Clinical Development Stage, Highly Selective RXR Nuclear Receptor Agonist Compound, Supporting its Potential Use for Treatment of Amyotrophic Lateral Sclerosis

Selasa, 16 Juli 2024 - 20:30:00 Wib
Globenewswire

Io Therapeutics, Inc., Presented Data from Studies of IRX4204, the Company’s Phase II Clinical Development Stage

Rabu, 10 Juli 2024 - 12:30:00 Wib
Globenewswire

Io Therapeutics, Inc., Announces Presentation of Data on Induction of Tumor Growth Inhibiting Anti-cancer Immune Responses in Multiple Types of Cancers by a IRX5010, a Novel Retinoic Acid Nuclear Receptor Agonist Compound

Selasa, 09 Juli 2024 - 20:55:21 Wib
Globenewswire

Io Therapeutics, Inc., Announces Publication of Data on a Novel Compound Promoting Anti-Cancer Immune Responses

Selasa, 12 September 2023 - 22:03:00 Wib